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Objective/Background: Isoniazid (INH) is one of the effective antituberculosis (TB) drugs used
for TB treatment. However, most of the drug-resistant Mycobacterium tuberculosis (MTB)
clinical strains are resistant to INH, a first-line antituberculous drug. Certain metabolic
enzymes such as adenosylhomocysteinase (Rv3248c), universal stress protein (Rv2623),
nicotinamide adenine dinucleotide (reduced)-dependent enoyl-acyl carrier protein
reductase (Rv1484), oxidoreductase (Rv2971), dihydrofolate reductase (Rv2763c), pyrroline-
5-carboxylate dehydrogenase (Rv1187) have been identified to bind INH–nicotinamide
adenine dinucleotide (INH–NAD) and INH–nicotinamide adenine dinucleotide phosphate
adducts coupled to Sepharose resin. These enzymes are reported to be involved in many
important biochemical processes of MTB, including cysteine and methionine metabolism,
mycobacterial growth regulation, mycolic acid biosynthesis, detoxification of toxic
metabolites, folate biosynthesis, etc. The truncated INH–nicotinamide adenine
dinucleotide (oxidized) adduct, 4-isonicotinoylnicotinamide, isolated from urine samples
of human TB patients treated with INH therapy is proposed to have antimycobacterial
activity.
Methods: To understand the mechanism of interaction of the truncated INH–NAD adduct,
binding energy studies were carried out on the aforementioned six enzymes with known
three-dimensional structures using AutoDock4.2.
Results: In silico docking analysis of these MTB enzymes with the truncated INH–NAD
adduct showed favorable binding interactions with docking energies ranging from 5.29
to 7.07 kcal/mol.
Conclusion: Thus, in silico docking study revealed that the INH–NAD adduct, which is
generated in vivo after INH activation, may undergo spontaneous hydrolysis to form them 442 102
Fig. 1 – Chemical structur
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addition to InhA, confirming that INH is an effective anti-TB drug acting at multiple
enzymes. Further analysis of amino acid residues in the active site of INH–NAD-binding
proteins showed the probable presence of catalytic triad in four enzymes possibly involved
in INH binding to the enzyme.
 2015 Asian African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
All rights reserved.Introduction
Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB),
is a major cause of morbidity and mortality worldwide.
Globally, 33% of the population is considered to be infected
with MTB, with 9.0 million new patients and 1.5 million
deaths in the year 2013, including 360,000 deaths among
human immunodeficiency virus (HIV)-positive individuals.
India and China had the largest number of TB cases (24%
and 11%, respectively) of the total cases identified [1]. In addi-
tion, multidrug-resistant strains of MTB in association with
HIV have further created a fearsome aspect to the problem
[2]. The current epidemics of extensively drug-resistant TB
have also been an increasing threat in some regions around
the world [3]. Most drug-resistant clinical strains of MTB are
resistant to isoniazid (INH, isonicotinic acid hydrazide), a
first-line antituberculous drug [4].
INH (Fig. 1) is one of the most effective anti-TB drugs for
prevention and treatment of TB. It inhibits the synthesis of
mycolic acids, a vital component of the bacterial cell wall.
At therapeutic levels, INH is bacteriocidal against actively
growing intracellular and extracellular MTB. Under multidrug
therapy, it is used in conjunction with other effective anti-TB
agents [5].
Mechanisms of action of INH
The mechanism of INH action has been the subject of exten-
sive studies. It is reported to generate a variety of highly reac-
tive compounds, including reactive oxygen species such as
superoxide, peroxide, and hydroxyl radical [6], nitric oxide
[7], reactive organic species such as isonicotinic acyl radical
or anion [8], and certain electrophilic species [9], which then
attack multiple targets in MTB cases [10,11]. INH is a prodrug,
that is, it requires activation before it becomes therapeutically
effective. This process is carried out by the catalase–peroxi-
dase activity of the katG gene product, and mutations in the
katG gene contribute to resistance to INH [12]. INH passively
diffuses through the mycobacterial envelope, where it is acti-
vated by MnCl2 and catalase–peroxidase of the katG possiblye of isoniazid (formulainto an isonicotinoyl radical or anion. Modified INH appears
to covalently attach itself to nicotinamide adenine
dinucleotide (oxidized) (NAD+) to form an INH–NAD adduct,
which inhibits the synthesis of mycolic acid. Stigliani et al.
[13] studied the binding of the tautomeric forms of INH–
NAD adducts to the active site of InhA and noted that the
4S-chain adduct is the effective active form of the INH–NAD
adducts. Mahapatra et al. [14] in their mass spectrometry
study isolated a novel metabolite—4-isonicotinoylnicotina
mide (4-INN), a truncated part of the INH–NAD adduct—from
urine samples of human TB patients who received INH ther-
apy. The truncated INH–NAD+ adduct with some structural
similarity to 4-INN was evaluated as an effective inhibitor of
InhA. Their test results indicated antimycobacterial activities
for the truncated INH–NAD+ adduct [15]. It has previously
been shown that INH is activated to the INH–NAD adduct by
katG of MTB. This truncated INH–NAD adduct then binds to
InhA [2-trans-enoyl-acyl carrier protein-(ACP) reductase] and
eventually causes inhibition by computational approach [16].
Interestingly, arylamine N-acetyltransferase (NAT), a drug-
metabolizing enzyme of MTB, can acetylate INH, transferring
an acetyl group from acetyl coenzyme A to the terminal
nitrogen of the drug, which in its N-acetylated form is
therapeutically inactive [12]. The overexpression of NAT in
Mycobacterium smegmatis showed increased resistance to INH
[17]; in addition, when the gene was knocked-out, the bacteria
exhibited increased sensitivity to INH [18]. Therefore, it is
likely that NAT competes with katG for INH [19] (Fig. 2).
High-affinity INH–NAD(P)-binding proteins
Both nicotinamide adenine dinucleotide (reduced)-dependent
enoyl-(ACP) reductase [NADH-dependent enoyl-(ACP) reduc-
tase; InhA] and the nicotinamide adenine dinucleotide
phosphate-dependent dihydrofolate reductase (DHFR; DfrA)
have been shown to be inhibited by the INH–NAD(P) adducts
with nanomolar affinity. Argyrou et al. [20] have shown that
in addition to InhA and DfrA, 15 other proteins bind these
adducts coupled to Sepharose resin with high affinity
(Table 1).: C6H7N3O; molecular weight: 137.139 g/mol).
Table 1 – High-affinity INH–NAD(P)-binding proteins from Mycob
Locus Name Str
Rv3248c S-adenosyl-L-homocysteine hydrolase 3D
Rv0753c Methylmalonate-semialdehyde dehydrogenase —
Rv1187 Pyrroline-5-carboxylate dehydrogenase (RocA) 4IH
Rv0155 NAD(P) transhydrogenase subunit alpha —
Rv2623 Universal stress protein 3CI
Rv1996 Hypothetical protein —
Rv0468 3-Hydroxybutyryl-CoA dehydrogenase —
Rv1484 Enoyl-ACP reductase 1P4
Rv2691 TRK system potassium-uptake protein CEOB —
Rv0091 Bifunctional 5-methylthioadenosine
nucleosidase/S-adenosylhomocysteine
nucleosidase
—
Rv2858c Aldehyde dehydrogenase —
Rv1059 Hypothetical protein —
Rv3777 Oxidoreductase —
Rv2971 Oxidoreductase 4O
Rv2766c 3-Ketoacyl-ACP reductase —
Rv2671 Hypothetical protein —
Rv2763c Dihydrofolate reductase 4K
Note: ACP = acyl carrier protein; ATP = adenosine triphosphate; CoA = coen
(reduced); NADP = nicotinamide adenine dinucleotide phosphate; CEOB
Transporter.
Fig. 2 – Schematic showing the activation and inactivation of
INH [12]. INH is a prodrug and requires activation by the
catalase– peroxidase protein (theKatGgene product). The NAT
enzymes can N-acetylate INH, rendering the drug therapeu-
tically inactive. The asterisk next to the terminal nitrogen in
the active form of INH denotes a range of oxidized species [19].
Note: INH = isoniazid; NAT = N-acetyltransferase.
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(Rv3248c), universal stress protein (Rv2623), NADH-
dependent enoyl-(ACP) reductase (Rv1484), oxidoreductase
(Rv2971), DHFR (Rv2763c), and pyrroline-5-carboxylate
dehydrogenase (Rv1187)] have known experimentally deter-
mined three-dimensional (3D) structure available at the
Protein Data Bank (PDB). Mahapatra et al. [14] observed that
the formation of 4-INN (a truncated INH–NAD adduct)
occurred due to spontaneous hydrolysis of the INH–NAD+
adduct under in vitro INH activation condition, and this com-
pound has potential antimycobacterial activity. In this study,
we explored the interaction of the truncated INH–NAD
adduct with these six proteins through molecular docking
analysis.
Materials and methods
Hardware and software
The study was carried out on a Dell workstation with a
2.26-GHz processor, 6-GB RAM, and 500-GB hard drive running
a Windows operating system. Bioinformatics software,
such as AutoDock4.2, and online resources were used in this
study.acterium tuberculosis.
ucture Function
HY Thioester hydrolase acting on ether bounds. Could
be involved in methionine and selenoamino acid
metabolisms
Plays a role in valine and pyrimidine metabolism
I Involved in the arginase pathway
Involved in the transhydrogenation between NADH
and NADP, which is coupled to respiration and ATP
hydrolysis
S May play a role in the establishment of a persistent
infection (latency) in the host, as strains without
this gene are hypervirulent.
Function unknown
Butyrate/butanol-producing pathway
4 This isozyme is involved in mycolic acid
biosynthesis
Part of a potassium-transport system
Responsible for cleavage of the glycosidic bond in
both 5 0-methylthioadenosine and S-
adenosylhomocysteine
Oxidizes a wide variety of aldehydes
Function unknown
Function unknown; probably involved in cellular
metabolism
TK Function unknown; probably involved in cellular
metabolism
Function unknown; possibly involved in cellular
metabolism
Involved in riboflavin biosynthesis
L9 Involved in an essential step for de novo glycine and
purine synthesis
zyme A; INH = isoniazid; NADH = nicotinamide adenine dinucleotide
= complement the E. coli OxyR-knockout mutant type B; TRK = K+
Fig. 3 – Docking interaction of truncated INH–NAD adduct with (A) Rv2971, (B) Rv2623, (C) Rv3248c, (D) Rv1484, (E) Rv2763c, and
(F) Rv1187 showing hydrogen bonds in dotted lines. Note: INH = isoniazid; NAD = nicotinamide adenine dinucleotide.
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High-affinity INH–NAD(P)-binding proteins of MTB (Rv2623,
Rv3248c, Rv2971, Rv2763c, Rv1484, and Rv1187) are reported
to have high binding affinity for INH–NAD(P) [20]. The experi-
mentally determined structures of these proteins obtained
through X-ray diffraction experiment are available at the
PDB. The 3D structures of Rv2623 (PDB ID 3CIS), Rv3248c
(PDB ID 3DHY), Rv2971 (PDB ID 40TK), Rv2763c (PDB ID
4KL9), Rv1484 (PDB ID 1P44), and Rv1187 (PDB ID 4IHI) were
retrieved from PDB for the docking study.
Ligand preparation
Because the 3D conformer generation of the INH–NAD adduct
is disallowed due to too many atoms [21], the PRODRG2 server
[22] was used to obtain the chemical structure of the trun-
cated INH–NAD adduct in PDB format.
Protein–ligand docking
Protein–ligand docking studies were performed using
AutoDock4.2 [23]. This is one of the most widely used methods
for protein–ligand docking. All the preprocessing steps for
ligand and protein files were performed using the AutoDock
Tools 1.5.4 program (ADT), which had been released as an
extension suite to the Python Molecular Viewer [23]. The ADT
program was used to prepare receptor molecules [high-affinity
INH–NAD(P)-binding proteins of MTB] by adding all hydrogen
atoms to carbon atoms of the receptor; in addition, Kollman
charges were also assigned. For docked ligands, nonpolar hydro-
gens were also added. Gasteiger charges were assigned and tor-
sions degrees of freedom were allocated by the ADT program.
The Lamarckian genetic algorithm (LGA) was applied to
model the interaction pattern between receptors and ligand.
The grid maps representing the receptor proteins in the docking
process were prepared using AutoGrid (part of the AutoDock
package). A grid of 40, 40, and 40 points in the x, y, and z direc-
tions was centered on the known active-site residues of each
protein. For all docking procedures, 10 independent genetic
algorithm (GA) runs with a population size of 150 were consid-
ered for each molecule studied. A maximum number of
25 · 105 energy evaluations; 27,000 maximum generations; a
gene mutation rate of 0.02, and a crossover rate of 0.8 were used
for LGA [16]. The AutoDock program was run to prepare the cor-
responding docking log (.dlg) file for further analysis.
Visualization
The visualization of structure files was carried out using the
graphical interface of the ADT program and PyMol molecular
graphics system (www.pymol.org).
Results
Docking analysis of high-affinity INH–NAD(P)-binding
proteins of MTB and truncated INH–NAD adduct
In this study, docking analysis was performed between
selected INH–NAD(P)-binding proteins and truncatedINH–NAD adduct around known active-site residues of
respective proteins. Among the six selected proteins, the
truncated INH–NAD adduct binds to Rv2971 (Fig. 3A) with
lowest binding energy of 7.07 kcal/mol and with inhibition
constant of 6.62 lM (Table 2). The docking of Rv2623 with
the truncated INH–NAD adduct was performed around
reported substrate-binding-site residues Asp167 and Asp198.
The adduct binds to Rv2623 with binding energy of
7.06 kcal/mol and inhibition constant of 6.72 lM. It forms
three hydrogen bonds with these binding-site residues
(Fig. 3B). Glu218, Lys248, and Asp252 are known binding-site
residues of Rv3248c. Rv3248c binds to the truncated INH–
NAD adduct (Fig. 3C) with binding energy of 7.05 kcal/mol
and inhibition constant of 6.83 lM. We also performed a dock-
ing analysis between InhA and truncated INH–NAD adduct
around known substrate-binding residue Tyr158 [24]. The
truncated INH–NAD adduct binds to InhA with binding energy
of –6.86 kcal/mol and with inhibition constant of 9.30 lM. It
also formed one hydrogen bond with known binding-site resi-
due Tyr158 (Fig. 3D).
The other two proteins (Rv2763c and Rv1187) interact with
the truncated INH–NAD adduct (Fig. 3E and F) with binding
energy of 6.42 and 5.29 kcal/mol, respectively, and inhibi-
tion constant of 19.57 and 132.67 lM, respectively.Discussion
Mahapatra et al. [14] observed the formation of a truncated
INH–NAD adduct due to spontaneous hydrolysis of the INH–
NAD+ adduct under in vitro INH activation condition and sta-
ted that there was a possibility of enzymatic hydrolysis of the
INH–NAD+ adduct in vivo, because of the presence of several
NAD-degrading enzymes in mammals. Thus, to study the
potential antimycobacterial activity of the truncated INH–
NAD adduct, we applied the same principle for the docking
analysis of MTB enzymes with the reported INH–NAD-
binding proteins using AutoDock4.2. The scoring algorithm
of AutoDock signifies that lower the binding energy (binding
energy is given in the negative sign) better the binding affinity
[25]. AutoDock is tested as reliable software to precisely pre-
dict the binding affinity of a ligand to a protein [23,25]. Of
the six selected proteins, three proteins, namely, Rv2971 (oxi-
doreductase), Rv2623 (universal stress protein), and Rv3248c
(S-adenosyl-L-homocysteine hydrolase), were found to inter-
act with the truncated INH–NAD adduct with almost similar
binding energies (Table 2).
The protein Rv2971 belongs to the aldo–keto reductases
family of MTB and plays an important role in the detoxifica-
tion of toxic metabolites. Recently, it has been reported as a
new target of INH [26], which correlates with our docking
study results, which showed inhibition of its activity by the
truncated INH–NAD adduct with minimum binding energy
of 7.07 kcal/mol. A universal stress protein encoded by
MTB Rv2623 helps in regulation of mycobacterial growth both
in vitro and in vivo [24]. It also binds adenosine triphosphate
(ATP) and may function as an ATP-dependent signaling inter-
mediate in a pathway that promotes persistent infection [24].
Jain et al. [27] also suggested Rv2623 as a potential biomarker
for the diagnosis of the latent as well as active MTB
Table 3 – Amino acid residues in the active site of INH–NAD-binding proteins.
Protein Active-site residues Known
catalytic triad
Acidic Basic Nucleophilic Neutral
(polar) Uncharged
Aromatic Aliphatic
(nonpolar)
neutral
Rv2971 Asp52
Glu274
Arg273,
Lys82,
His115
Tyr57,
Tyr194,
Tyr279,
Gln168,
Ser146,
Asn147,
Trp116,
Thr282
Trp116 Ala56 Tyr, Lys, Asp
(Reported in [32])
Rv2623 Asp198,
Asp167
Arg266,
Arg264,
His194
Ser172,
Pro245
Gly165,
Gly265,
Val166,
Val277,
Leu193,
Leu249,
Ala195
Rv3248c Asp156,
Asp252,
Glu218
His69,
His416,
Lys248
Thr219,
Asn409,
Asn253,
Ser424,
Thr71
Phe425 Val286,
Met421,
Gly415,
Leu68,
Leu410,
Leu407
Lys248,
Asp252,
Asn253
(Probable)
Rv1484 Asp148 Lys165 Tyr158,
Pro193,
Thr196
Tyr158,
Phe149
Met147,
Met199,
Ala191,
Ile194,
Gly192
Tyr158,
Lys165,
Phe149
(Reported in [33])
Rv2763c Asp27,
Glu111
His30,
Arg23
Thr113,
Gln28,
Tyr100,
Trp6
Phe31 Lue24,
Ile5,
Ala7
His30,
Asp27
(Probable)
Rv1187 Asp244 His272,
Lys212
Thr269,
Trp276,
Tyr184,
Ser249
Phe246 Ile186,
Gly245,
Leu273,
Leu253
Table 2 – Docking analysis of the truncated INH–NAD adduct with MTB Proteins.
Locus Protein Known active-site residues Binding energy
(kcal/mol)
Inhibition
constant (lM)
Rv2971 Oxidoreductase Tyr57
His115
7.07 6.62
Rv2623 Universal stress protein Asp167, Asp198 7.06 6.72
Rv3248c S-adenosyl-L-homocysteine
hydrolase
Thr71, Asp156,
Glu218,
Lys248,
Asp252,
Asn253,
Glu305,
Asn340,
Asn409
7.05 6.83
Rv1484 NADH-dependent enoyl-(ACP)
reductase
Tyr158 6.86 9.30
Rv2763c Dihydrofolate reductase Asp27, Arg32, Arg60,
Gly80, Tyr100, Thr113
6.42 19.57
Rv1187 Pyrroline-5-carboxylate
dehydrogenase
Lys212, Ser249,
Cys327, Phe427
5.29 132.67
Note: ACP = acyl carrier protein; INH = isoniazid; MTB = Mycobacterium tuberculosis; NAD = nicotinamide adenine dinucleotide;
NADH = nicotinamide adenine dinucleotide (reduced).
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NAD adduct with formation of H-bond with the ATP-binding-
site residues of the Rv2623 suggests the truncated adduct as
possible inhibitor of the protein. Rv3248c codes S-adenosyl-
L-homocysteine hydrolase (Mtb-SahH) in MTB, which is an
essential enzyme for optimal growth of the pathogen and is
involved in intermediary metabolism. Singhal et al. [28] also
revealed its involvement in regulating homocysteine concen-
tration in surrogate host M. smegmatis [28]. The truncated
adduct also observed to inhibit Rv3248c. INH was reported
to act on MTB by inhibiting a 2-trans-enoyl-(ACP) reductase
(InhA), which is encoded by Rv1484 [4]. The INH–NAD adduct
was also demonstrated to be a capable InhA inhibitor [29,30].
This in silico docking study correlates with an earlier in vitro
study by Nguyen et al. [30], who reported the INH–NAD adduct
as a powerful inhibitor of InhA. MTB DHFR encoded by
Rv2763c was reported as an essential enzyme for nucleic acid
synthesis. Argyrou et al. [20] observed the inhibition of MTB
DHFR by acyclic 4R isomer of the INH–nicotinamide adenine
dinucleotide phosphate adduct. The pyrroline-5-carboxylate
dehydrogenase encoded by Rv1187 was shown to be involved
in the proline-utilization pathway in MTB and this pathway
could be a valuable therapeutic target against TB [31]. All
the six proteins of MTB are found to be essential for the
pathogenic organism and our in silico docking study also
revealed the effective inhibition of these proteins by the trun-
cated INH–NAD adduct, which can explain the effectiveness
of INH as an anti-TB drug.
Further, upon active-site analysis of these six proteins, we
observed that of the six proteins, two proteins (Rv2971 and
Rv1484) have known catalytic triad in their active site
(Table 3). Three amino acids (Tyr57, Lys82, and Asp52) were
reported as catalytic triad in Rv2971 [32], whereas Tyr158,
Lys165, and Phe149 act as catalytic triad in Rv1484 [33]. A cat-
alytic triad usually refers to the three amino acid residues
that function together at the center of the active site of cer-
tain hydrolases and transferases (e.g., proteases, amidases,
esterases, acylases, lipases, and b-lactamases). Gupta et al.
[34] observed that in case of catalytic triad, the hydrogen bond
distance between the Hc atom nucleophilic residue (such as
Ser Hc) and Ne2 atom of basic residue (such as His) is more
flexible in nature and varied from 2.0 to 2.7 A˚, whereas the
distance between Hd1 of basic (such as His) and Od1 of acidic
residues (e.g., Asp) varied from 1.6 to 2.0 A˚. Based on the
H-bond distance criteria, two other proteins, namely,
Rv3248c and Rv2763c, are proposed to have probable catalytic
triad (Table 3). The catalytic triad may have some important
role in INH binding and needs to be further investigated.
Conclusion
We have applied the computational approach to study the
interaction between truncated INH–NAD adduct and INH–
NAD(P)-binding proteins. The in silico docking study revealed
that the truncated adduct might indeed bind to the selected
proteins. Further, the interaction between the truncated
adduct and these proteins indicates the presence of a cat-
alytic triad in the active site of some of these proteins, which
may possibly play a role in INH binding, but this needs furtherinvestigation. In this study, we have included only those pro-
teins with known experimentally determined 3D structure.
The interaction of other INH–NAD(P)-binding proteins, whose
3D structures are not available, needs to be explored further
to understand the mechanism of action of INH as an anti-
TB drug acting on multiple enzymes.
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